Welcome to Francis Academic Press

Academic Journal of Medicine & Health Sciences, 2023, 4(9); doi: 10.25236/AJMHS.2023.040905.

Research Progress on the Mechanism of Gut Microbiota in Liver Diseases


Jinghua Hui1, Ting Lei2, Taotao Yin1, Yixiong Fang1

Corresponding Author:
Ting Lei

1Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China

2Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China


Gut microbiota (GM) dysbiosis can lead to the development of many diseases, and maintaining the stability of the gut microbiota is essential for the body to resist damage from the external environment. The liver is intrinsically linked to the gastrointestinal tract through the biliary tract, portal vein, and body circulation, and this intrinsic link is known as the "gut-liver axis". This "communication" between the intestine and the liver is the key to maintaining normal liver metabolism and intestinal homeostasis, and the two influence each other as cause and effect. The gut microbiota participates in a series of physiopathological reactions through the gut-liver axis, which ultimately affects the occurrence of liver diseases. In this paper, we will describe the relationship between gut microbiota and various liver diseases as well as the mechanism of gut microbiota in liver diseases, to provide theoretical reference for the prevention and treatment of liver diseases.


Gut microbiota, Gut-liver axis, Liver disease, Intestinal barrier

Cite This Paper

Jinghua Hui, Ting Lei, Taotao Yin, Yixiong Fang. Research Progress on the Mechanism of Gut Microbiota in Liver Diseases. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 9: 28-33. https://doi.org/10.25236/AJMHS.2023.040905.


[1] Wan M, Ling K H, El-Nezami H, et al. Influence of functional food components on gut health[J]. Crit Rev Food Sci Nutr, 2019, 59(12):1927-1936. 

[2] Ye X, Wang A, Lin W, et al. The Role of gut microbiota in Anti-Tumor Antibiotic Therapy[J]. Front Biosci (Landmark Ed), 2022, 27(10):281. 

[3] Rinninella E, Raoul P, Cintoni M, et al. What is the Healthy Gut Microbiota Composition? a Changing Ecosystem across Age, Environment, Diet, and Diseases[J]. Microorganisms, 2019, 7(1). 

[4] Milosevic I, Vujovic A, Barac A, et al. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: a Review of the Literature[ J]. Int J Mol Sci, 2019, 20(2). 

[5] Li S, Han W, He Q, et al. Relationship between Intestinal Microflora and Hepatocellular Cancer Based on Gut-Liver Axis Theory[J]. Contrast Media Mol Imaging, 2022, 2022:6533628. 

[6] Wang L, Cao Z M, Zhang L L, et al. The Role of Gut Microbiota in Some Liver Diseases: from an Immunological Perspective[J]. Front Immunol, 2022, 13:923599. 

[7] Tripathi A, Debelius J, Brenner D A, et al. The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7):397-411. 

[8] Schwenger K J, Clermont-Dejean N, Allard J P. The role of the gut microbiome in chronic liver disease: the clinical evidence revised[J]. JHEP Rep, 2019, 1(3):214-226. 

[9] Anand S, Mande S S. Host-microbiome interactions: the Gut-Liver axis and its connection with other organs[J]. NPJ Biofilms Microbiomes, 2022, 8(1):89. 

[10] Yang X, Mai H, Zhou J, et al. Alterations of the gut microbiota associated with the occurrence and progression of viral hepatitis. [J]. Frontiers in cellular and infection microbiology, 2023, 13. 

[11] Sun Z, Huang C, Shi Y, et al. Distinct Bile Acid Profiles in Patients With Chronic Hepatitis B Virus Infection Reveal Metabolic Interplay Between Host, Virus and Gut Microbiome[J]. Front Med (Lausanne), 2021, 8:708495. 

[12] Wang T, Rong X, Zhao C. Circadian Rhythms Coordinated With Gut Microbiota Partially Account for Individual Differences in Hepatitis B-Related Cirrhosis[J]. Front Cell Infect Microbiol, 2022, 12:936815. 

[13] Li X, Wu S, Du Y, et al. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model[J]. Int J Antimicrob Agents, 2020, 56(1):106000. 

[14] Hsu Y C, Chen C C, Lee W H, et al. Compositions of gut microbiota before and shortly after hepatitis C viral eradication by direct antiviral agents[J]. Sci Rep, 2022, 12(1):5481. 

[15] Ashour Z, Shahin R, Ali-Eldin Z, et al. Potential impact of gut Lactobacillus acidophilus and Bifidobacterium bifidum on hepatic histopathological changes in non-cirrhotic hepatitis C virus patients with different viral load[J]. Gut Pathog, 2022, 14(1):25. 

[16] Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3):558-577. 

[17] Li G H, Li H L, Chen Z G, et al. Research progress on alcoholic liver disease and gut microbial[J]. Chinese Journal of Laboratory Animals, 2022, 30(03):423-427. 

[18] Litwinowicz K, Choroszy M, Waszczuk E. Changes in the composition of the human intestinal microbiome in alcohol use disorder: a systematic review[J]. Am J Drug Alcohol Abuse, 2020, 46(1):4-12. 

[19] Shukla P K, Meena A S, Rao V, et al. Human Defensin-5 Blocks Ethanol and Colitis-Induced Dysbiosis, Tight Junction Disruption and Inflammation in Mouse Intestine [J]. Sci Rep, 2018, 8(1):16241. 

[20] Seo B, Jeon K, Moon S, et al. Roseburia spp. Abundance Associates with Alcohol Consumption in Humans and Its Administration Ameliorates Alcoholic Fatty Liver in Mice[J]. Cell Host Microbe, 2020, 27(1):25-40. 

[21] Liu J, Kong L, Shao M, et al. Seabuckthorn polysaccharide combined with astragalus polysaccharide ameliorate alcoholic fatty liver by regulating gut microbiota[J]. Front Endocrinol (Lausanne), 2022, 13:1018557. 

[22] Kong L, Chen J, Ji X, et al. Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPARalpha to activate the NF-kappaB signaling pathway, thereby reducing liver injury via inducing gut microbiota disturbance[J]. J Exp Clin Cancer Res, 2021, 40(1):18. 

[23] Mendez-Sanchez N, Diaz-Orozco L E. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD) [J]. Med Sci Monit, 2021, 27:e933860. 

[24] Vallianou N, Christodoulatos G S, Karampela I, et al. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives[J]. Biomolecules, 2021, 12(1). 

[25] Jasirwan C, Lesmana C, Hasan I, et al. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms [J]. Biosci Microbiota Food Health, 2019, 38(3):81-88. 

[26] Mao J W, Tang H Y, Zhao T, et al. Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease[J]. Int J Clin Exp Pathol, 2015, 8(4):3648-3658. 

[27] Duan Y, Zeng L, Zheng C, et al. Inflammatory Links Between High Fat Diets and Diseases[J]. Front Immunol, 2018, 9:2649. 

[28] Ryu J, Kim E, Kang M K, et al. Differential TM4SF5-mediated SIRT1 modulation and metabolic signaling in nonalcoholic steatohepatitis progression[J]. J Pathol, 2021, 253(1):55-67. 

[29] Baffy G. Potential mechanisms linking gut microbiota and portal hypertension[J]. Liver Int, 2019, 39(4):598-609. 

[30] Oikonomou T, Papatheodoridis G V, Samarkos M, et al. Clinical impact of microbiome in patients with decompensated cirrhosis[J]. World J Gastroenterol, 2018, 24(34):3813-3820. 

[31] Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature, 2014, 513(7516):59-64. 

[32] Zheng R, Wang G, Pang Z, et al. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma[J]. Cancer Med, 2020, 9(12):4232-4250. 

[33] Munoz L, Borrero M J, Ubeda M, et al. Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis[J]. Hepatology, 2019, 70(3):925-938. 

[34] Yu L X, Schwabe R F. The gut microbiome and liver cancer: mechanisms and clinical translation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(9):527-539. 

[35] Schwabe R F, Greten T F. Gut microbiome in HCC - Mechanisms, diagnosis and therapy[J]. J Hepatol, 2020, 72(2):230-238. 

[36] Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma[J]. Gut, 2019, 68(6):1014-1023. 

[37] Gram A, Kowalewski M P. Molecular Mechanisms of Lipopolysaccharide (LPS) Induced Inflammation in an Immortalized Ovine Luteal Endothelial Cell Line ( OLENDO)[J]. Vet Sci, 2022, 9(3).